Psychedelics and suicidality: A double-edged sword - risks, mechanisms, and moving forward.
Maia Mallevays, Lucie Berkovitch
European Neuropsychopharmacology September 19, 2026 DOI: 10.1016/j.euroneuro.2026.113878 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Theoretical or philosophical paper Peer reviewed |
|---|---|
| Keywords | Mechanisms Psychedelics Risk-assessment Safety Suicide |
| Key points | The authors propose that psychedelics act as a "double-edge sword" for suicidality: the same psychological mechanisms—reduced fear of death, altered representations of the world, and reduced experiential avoidance—that may facilitate healing could, in vulnerable individuals or unsupportive contexts, precipitate destabilization and suicidal crises. They argue that adequate therapeutic support across screening, preparation, in-session guidance, and integration is essential to shift outcomes toward benefit. |
Abstract
Classic psychedelics, including lysergic acid diethylamide (LSD), psilocybin, and dimethyltryptamine (DMT), have re-emerged as promising treatments for psychiatric conditions linked to suicidality. However, rare reports of increased suicidality potentially associated with psychedelic use have raised safety concerns. This article examines the complex relationship between psychedelics and suicidality and develops a theoretical mechanistic model: the double-edge sword. We first summarise available data on suicide-related outcomes associated with psychedelic use reported in recreational settings and in first and second waves of clinical research. Several deaths have occurred following non-medical psychedelic use, where unsafe contexts led to accidents or presumed suicides, with unclear suicidal intent. Though less frequent, rare cases of increased suicidal ideation and behaviours have also been reported in clinical settings, without significant differences from placebo groups or established causality. We then offer a theoretical mechanistic framework encompassing both anti- and pro- suicidality mechanisms. Specifically, we propose three key psychological mechanisms - reduced fear of death, altered representations of the world and reduced experiential avoidance - constituting a double-edged sword: the same processes that facilitate healing may, in vulnerable individuals or unsupportive contexts, precipitate destabilisation and suicidal crises. Then, we turn to clinical practice recommendations aimed at harnessing these mechanisms for therapeutic benefit while mitigating suicide risk. Adequate therapeutic support, spanning screening, preparation, in-session guidance, and integration, seems essential to shifting outcomes toward benefit. Finally, we discuss future directions regarding potential psychedelic use in suicidal crises and propose guidelines to better study and characterise the underlying mechanisms driving this complex relationship.
Citations in the library
Cites 118
- Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial Journal of Psychopharmacology November 30, 2016
- Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial Journal of Psychopharmacology November 30, 2016
- Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance Psychopharmacology July 7, 2006
- Trial of Psilocybin versus Escitalopram for Depression New England Journal of Medicine April 14, 2021
- Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder JAMA Psychiatry November 4, 2020
and 113 more in the library